(Q34687109)

3 August 2017

1 reference

title

Newer positive inotropic agents in the treatment of chronic cardiac failure. Current status and future directions (English)

1 reference

3 August 2017

Weber KT

1

1 reference

3 August 2017

Gill SK

2

1 reference

3 August 2017

Janicki JS

3

1 reference

3 August 2017

Maskin CS

4

1 reference

3 August 2017

Jain MC

5

1 reference

3 August 2017

1 May 1987

1 reference

3 August 2017

1 reference

3 August 2017

33

1 reference

3 August 2017

5

1 reference

3 August 2017

503-519

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-198733050-00005

3 August 2017

0 references

cites work

Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle

1 reference

12 December 2020

Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.

1 reference

12 December 2020

The metabolic demand and oxygen supply of the heart: Physiologic and clinical considerations

1 reference

12 December 2020

The prevalence of congestive heart failure in two rural communities

1 reference

12 December 2020

Cardiopulmonary exercise testing for evaluation of chronic cardiac failure.

1 reference

12 December 2020

Amrinone in the treatment of chronic cardiac failure

1 reference

12 December 2020

A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity

1 reference

12 December 2020

Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

1 reference

12 December 2020

Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy

1 reference

12 December 2020

Pirbuterol, an oral beta-adrenergic receptor agonist, in the treatment of chronic cardiac failure

1 reference

12 December 2020

Inotropic drugs and their mechanisms of action

1 reference

12 December 2020

Impaired skeletal muscle nutritive flow during exercise in patients with congestive heart failure: role of cardiac pump dysfunction as determined by the effect of dobutamine

1 reference

12 December 2020

Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure

1 reference

12 December 2020

Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine.

1 reference

12 December 2020

Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure

1 reference

12 December 2020

Milrinone in the treatment of chronic cardiac failure: a controlled trial

1 reference

12 December 2020

Effect of hydralazine on perfusion and metabolism in the leg during upright bicycle exercise in patients with heart failure.

1 reference

12 December 2020

Factors influencing left ventricular shortening in isolated canine heart

1 reference

12 December 2020

Amrinone and exercise performance in patients with chronic heart failure

1 reference

12 December 2020

Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patients

1 reference

12 December 2020

Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity

1 reference

12 December 2020

Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure

1 reference

12 December 2020

The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy

1 reference

12 December 2020

Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure

1 reference

12 December 2020

Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure

1 reference

12 December 2020

Epidemiology of congestive heart failure

1 reference

12 December 2020

Acute effects of oral pirbuterol on myocardial oxygen metabolism and systemic hemodynamics in chronic congestive heart failure

1 reference

12 December 2020

Dobutamine in chronic ischemic heart failure: Alterations in left ventricular function and coronary hemodynamics

1 reference

12 December 2020

Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure

1 reference

12 December 2020

MDL 17,043: short- and long-term cardiopulmonary and clinical effects in patients with heart failure.

1 reference

12 December 2020

Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one]

1 reference

12 December 2020

Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure

1 reference

12 December 2020

Acute inotropic stimulation with dopamine in severe congestive heart failure: beneficial hemodynamic effect at rest but not during maximal exercise

1 reference

12 December 2020

Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failure

1 reference

12 December 2020

Piroximone (MDL 19,205) in the treatment of unstable and stable chronic cardiac failure

1 reference

12 December 2020

Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure

1 reference

12 December 2020

Inotropic therapy for refractory congestive heart failure with oral fenoximone (MDL-17,043): poor long-term results despite early hemodynamic and clinical improvement

1 reference

12 December 2020

Reduction of Digitalis Toxicity by Computer-Assisted Glycoside Dosage Regimens

1 reference

12 December 2020

Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure

1 reference

12 December 2020

MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response

1 reference

12 December 2020

Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man

1 reference

12 December 2020

Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study

1 reference

12 December 2020

Long-term vasodilator therapy for heart failure: clinical response and its relationship to hemodynamic measurements.

1 reference

12 December 2020

Pathophysiology of cardiac failure.

1 reference

12 December 2020

Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.

1 reference

12 December 2020

Improved catheter for regional coronary sinus flow and metabolic studies

1 reference

12 December 2020

Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease

1 reference

12 December 2020

Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure

1 reference

12 December 2020

Decreased Lymphocyte Beta-Adrenergic-Receptor Density in Patients with Heart Failure and Tolerance to the Beta-Adrenergic Agonist Pirbuterol

1 reference

12 December 2020

High prevalence of nonsustained ventricular tachycardia in severe congestive heart failure

1 reference

12 December 2020

Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failure

1 reference

12 December 2020

Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease.

1 reference

12 December 2020

Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure

1 reference

12 December 2020

Hemodynamic assessment of amrinone. A new inotropic agent

1 reference

12 December 2020

Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failure

1 reference

12 December 2020

Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure

1 reference

12 December 2020

New hope for the failing heart

1 reference

12 December 2020

Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol

1 reference

12 December 2020

Inotropic drugs in the treatment of heart failure

1 reference

12 December 2020

Relaxation abnormalities. Part I: Mechanisms

1 reference

12 December 2020

Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure

1 reference

12 December 2020

The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure

1 reference

12 December 2020

10.2165/00003495-198733050-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference